UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors

Future oncology (London, England), 2021-07, Vol.17 (21), p.2747-2758

2021

Volltextzugriff (PDF)

Danusertib, an aurora kinase inhibitor

Expert opinion on investigational drugs, 2012-03, Vol.21 (3), p.383-393

2012

Volltextzugriff (PDF)

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

Clinical cancer research, 2014-09, Vol.20 (18), p.4776-4783

2014

Volltextzugriff (PDF)

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Cancer chemotherapy and pharmacology, 2016-12, Vol.78 (6), p.1185-1197

2016

Volltextzugriff (PDF)

Role of pharmacogenetics in irinotecan therapy

Cancer letters, 2006-03, Vol.234 (1), p.90-106

2006

Volltextzugriff (PDF)

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

The oncologist (Dayton, Ohio), 2013-03, Vol.18 (3), p.323-329

2013

Volltextzugriff (PDF)

Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT083-CT083

2023

Volltextzugriff (PDF)

Abstract CT302: Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT302-CT302

2015

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.703-711

2005

Volltextzugriff (PDF)

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

The oncologist (Dayton, Ohio), 2006-09, Vol.11 (8), p.944-954

2006

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-05, Vol.11 (10), p.3806-3813

2005

Volltextzugriff (PDF)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Investigational new drugs, 2011-10, Vol.29 (5), p.953-962

2011

Volltextzugriff (PDF)

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

Anti-cancer drugs, 2001-06, Vol.12 (5), p.419-432

2001

Volltextzugriff (PDF)

Abstract A92: A phase 1 safety and pharmacokinetic study of navitoclax in combination with docetaxel in patients with solid tumors

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A92-A92

2011

Volltextzugriff (PDF)

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Clinical cancer research, 2005-02, Vol.11 (4), p.1504-1511

2005

Volltextzugriff (PDF)

Abstract C32: First-in-human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C32-C32

2009

Volltextzugriff (PDF)

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Clinical cancer research, 2006-05, Vol.12 (9), p.2841-2848

2006

Volltextzugriff (PDF)

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans

Anti-cancer drugs, 1999-09, Vol.10 (8), p.705-710

1999

Volltextzugriff (PDF)

Gender-dependent pharmacokinetics of topotecan in adult patients

Anti-cancer drugs, 2000-10, Vol.11 (9), p.673-680

2000

Volltextzugriff (PDF)

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

Anti-cancer drugs, 2002-07, Vol.13 (6), p.645-653

2002

Volltextzugriff (PDF)

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin

Anti-cancer drugs, 1999-01, Vol.10 (1), p.9-16

1999

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(16)
Oncology
(16)
Adult
(12)
Aged
(11)
Female
(11)
Male
(11)
Middle Aged
(11)
Neoplasms - Drug Therapy
(10)
Pharmacology & Pharmacy
(8)
Antineoplastic Agents - Pharmacokinetics
(7)
Camptothecin - Analogs & Derivatives
(7)
Neoplasms - Metabolism
(6)
Pharmacokinetics
(6)
Phase I
(6)
Antineoplastic Agents - Adverse Effects
(5)
Camptothecin - Pharmacokinetics
(5)
Dose-Response Relationship, Drug
(5)
Irinotecan
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors

Danusertib, an aurora kinase inhibitor

Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Role of pharmacogenetics in irinotecan therapy

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study

Abstract CT302: Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

Abstract A92: A phase 1 safety and pharmacokinetic study of navitoclax in combination with docetaxel in patients with solid tumors

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Abstract C32: First-in-human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans

Gender-dependent pharmacokinetics of topotecan in adult patients

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin

Suchergebnisse filtern